ArticleTranslational oncology2026
Galectin-7 as a biomarker for aggressiveness and poor prognosis in thymic epithelial tumors.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo identify molecular determinants of tumor aggressiveness in TETs and to elucidate their functional roles and underlying mechanisms in tumor progression.
methodsWe performed proteomic profiling using data-independent acquisition mass spectrometry on 40 TET samples and their paired adjacent normal tissues to explore potential molecular differences. TETs were stratified into high-risk (WHO types B2, B3, and thymic carcinoma) and low-risk (types A, AB, and B1) groups based on histological classification. Gene set enrichment analysis (GSEA) was applied to the proteomic data to delineate pathways enriched in high-risk tumors. A validation cohort comprising 164 TET patients, along with 6 non-TET controls, was analyzed to assess Galectin-7 expression by immunohistochemistry and to evaluate its prognostic value. To further explore the biological role of Galectin-7, functional assays were performed in Tc1889 cells following Galectin-7 overexpression.
resultsProteomic analysis revealed Galectin-7 as a highly upregulated protein in high-risk TETs. GSEA analysis identified enrichment of mitochondrial and extracellular matrix-related pathways in high-risk tumors. Immunohistochemistry showed Galectin-7 expression in 82 % of high-risk TETs and only 13 % of low-risk TETs (p < 0.001), with higher expression correlating with advanced tumor stage and reduced progression-free survival. Functional assays demonstrated that Tc1889 cells with Galectin-7 overexpression exhibited enhanced proliferation and invasion. Additionally, MAPK signaling pathway activation was observed in Galectin-7-overexpressing cells.
conclusionsGalectin-7 is a potential biomarker for aggressive TETs, with expression levels associated with features of poor prognosis. These findings provide insight into TET biology and support further exploration of Galectin-7 in tumor stratification and therapeutic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.